Karyopharm Therapeutics Inc
KPTI6.940USD
+0.570+8.95%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
60.39MMarket Cap
LossP/E TTM
More Details of Karyopharm Therapeutics Inc Company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc Info
Ticker SymbolKPTI
Company nameKaryopharm Therapeutics Inc
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Number of employees279
Security typeOrdinary Share
Fiscal year-endNov 06
Address85 Wells Avenue
CityNEWTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02459
Phone16176580600
Websitehttps://karyopharm.com/
Ticker SymbolKPTI
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Company Executives of Karyopharm Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
13.51%
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
Adage Capital Management, L.P.
2.47%
The Vanguard Group, Inc.
2.39%
Other
71.45%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
13.51%
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
Adage Capital Management, L.P.
2.47%
The Vanguard Group, Inc.
2.39%
Other
71.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.95%
Hedge Fund
9.84%
Corporation
4.60%
Investment Advisor/Hedge Fund
2.40%
Individual Investor
2.32%
Venture Capital
0.92%
Research Firm
0.71%
Bank and Trust
0.06%
Other
60.18%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
251
4.11M
24.14%
-1.36M
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
728.77K
8.4%
+589.12K
+421.87%
Jun 30, 2025
J. Wood Capital Advisors LLC
458.13K
5.28%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.86%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
518.27K
5.98%
+7.97K
+1.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
184.85K
2.13%
-3.16K
-1.68%
Jun 30, 2025
Catalio Capital Management, LP
146.01K
1.68%
-9.61K
-6.17%
Jun 30, 2025
Avidity Partners Management LP
134.57K
1.55%
--
--
Jun 30, 2025
Marshall Wace LLP
128.45K
1.48%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
FAQs
Who are the top five shareholders of Karyopharm Therapeutics Inc?
The top five shareholders of Karyopharm Therapeutics Inc are:
T. Rowe Price Investment Management, Inc. holds 728.77K shares, accounting for 8.40% of the total shares.
J. Wood Capital Advisors LLC holds 458.13K shares, accounting for 5.28% of the total shares.
Adage Capital Management, L.P. holds 421.32K shares, accounting for 4.86% of the total shares.
The Vanguard Group, Inc. holds 518.27K shares, accounting for 5.98% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 184.85K shares, accounting for 2.13% of the total shares.
T. Rowe Price Investment Management, Inc. holds 728.77K shares, accounting for 8.40% of the total shares.
J. Wood Capital Advisors LLC holds 458.13K shares, accounting for 5.28% of the total shares.
Adage Capital Management, L.P. holds 421.32K shares, accounting for 4.86% of the total shares.
The Vanguard Group, Inc. holds 518.27K shares, accounting for 5.98% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 184.85K shares, accounting for 2.13% of the total shares.
What are the top three shareholder types of Karyopharm Therapeutics Inc?
The top three shareholder types of Karyopharm Therapeutics Inc are:
T. Rowe Price Investment Management, Inc.
Opaleye Management Inc.
J. Wood Capital Advisors LLC
T. Rowe Price Investment Management, Inc.
Opaleye Management Inc.
J. Wood Capital Advisors LLC
How many institutions hold shares of Karyopharm Therapeutics Inc (KPTI)?
As of 2025Q3, 251 institutions hold shares of Karyopharm Therapeutics Inc, with a combined market value of approximately 4.11M, accounting for 24.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -24.51%.
What is the biggest source of revenue for Karyopharm Therapeutics Inc?
In --, the -- business generated the highest revenue for Karyopharm Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
